Innovations in type 1 diabetes mellitus

Authors

  • María Laura Pomares Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires, Argentina
  • Alejandro De Dios Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v49i3.631

Keywords:

innovations, type 1 diabetes mellitus

Abstract

For more than 2,000 years, diabetes mellitus was considered a devastating and deadly disease. Through the centuries and from the first descriptions of the disease in the Ebers Papyrus, greater precision was obtained regarding its symptoms and pathophysiology. Since the discovery and application of insulin at the University of Toronto by researchers Banting, Macleod, Best, and Collip in 1921-1922, few drugs have been as noble and effective in the specific treatment of a disease as insulin. for the treatment of type 1 diabetes mellitus (DM1)1.

Author Biographies

María Laura Pomares, Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires, Argentina

Coordinator of the Graduates Committee

Alejandro De Dios, Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires, Argentina

Secretary of the Graduates Committee

References

I. Atkinson MA, George S. Eisenbarth 1947-2012, In Memorial. Diabetología 2013, 56: 435- 438.

II. Thomas D, Jan BO. New insulins and insulin therapy. Diabetes Technology & Therapeutics; 2014 16, S1:34- s43.

III. Weisserg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy. A meta-analysis. Diabetes Care 26:1079-1087, 2003.

IV. Langendam M, Luijf YM, Hooft L, et al. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst. Rev. 2012 Jan 18.

V. Atkinson MA, Von Herrat M, Powers AC, et al. Current concepts on the pathogenesis of type 1 diabetes: considerations for attempts to prevent and reverse the disease. Diabetes Care 2015, 38: 979- 988.

VI. Gruessner AC, Gruessner RWG. Pancreas transplant outcomes for United States and non United States cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of December 2011. Clin. Transpl. 23-40 (2012).

VII. Pereyra-Bonnet F, Gimeno ML, Argumedo NR, Ielpi M, Cardozo JA, Giménez CA, Hyon SH, Balzaretti M, Loresi M, Fainstein-Day P, Litwak LE, Argibay PF. Skin fibroblasts from patients with type 1 diabetes (T1D) can be chemically transdifferentiated into insulin-expressing clusters: a transgene-free approach. PLoS One. 2014 Jun 25; 9(6):e10036.

VIII. Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care. 2015. 38:1036-1043.

Downloads

Published

2023-12-21

How to Cite

Pomares, M. L., & De Dios, A. (2023). Innovations in type 1 diabetes mellitus. Journal of the Argentine Society of Diabetes, 49(3), 1–2. https://doi.org/10.47196/diab.v49i3.631

Issue

Vol. 49 No. 3 (2015): September/December 2015. Supplement of the XVI Conference of Graduates in Diabetes

Section

Editorial

License

Copyright (c) 2015 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3